Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
3billion, |
RCV001808287 | SCV002058952 | uncertain significance | Cockayne syndrome type 2 | 2022-01-03 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000042, PM2_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.806, PP3_P). Therefore, this variant is classified as uncertain significance according to the recommendation of ACMG/AMP guideline. |
Fulgent Genetics, |
RCV002482341 | SCV002796888 | uncertain significance | DE SANCTIS-CACCHIONE SYNDROME; Cerebrooculofacioskeletal syndrome 1; Cockayne syndrome type 2; UV-sensitive syndrome 1; Age related macular degeneration 5; Premature ovarian failure 11; Lung cancer | 2022-05-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002541471 | SCV003287033 | likely benign | not provided | 2025-01-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163947 | SCV003872097 | uncertain significance | Inborn genetic diseases | 2023-03-06 | criteria provided, single submitter | clinical testing | The c.2212A>C (p.I738L) alteration is located in exon 11 (coding exon 10) of the ERCC6 gene. This alteration results from a A to C substitution at nucleotide position 2212, causing the isoleucine (I) at amino acid position 738 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |